Presentation delivered by Claudia Stein, Director, Division of Information, Evidence, Research and Innovation, on 15 September 2015, at the 65th session of the WHO Regional Committee for Europe (Vilnius, Lithuania, 14–17 September 2015)
Contemporary health policy context in Europe: some opportunities and challenges
Presentation by Dr Zsuzsanna Jakab, WHO Regional Director for Europe. 8 March 2017, Israel
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe, at the School of Public Health Management (Chisinau, Republic of Moldova, 24 November 2016)
Presented by Piroska Östlin, Director and Åsa Nihlén, Technical Officer, Division of Policy and Governance for Health and Well-being, WHO/Europe, at the 66th session of the WHO Regional Committee for Europe.
Presentation by Dr Zsuzsanna Jakab,WHO Regional Director for Europe, at the Third High-level Meeting of the Small Countries Initiative, in Monaco, on 11–12 October 2016
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Annette Verster, WHO
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Contemporary health policy context in Europe: some opportunities and challenges
Presentation by Dr Zsuzsanna Jakab, WHO Regional Director for Europe. 8 March 2017, Israel
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe, at the School of Public Health Management (Chisinau, Republic of Moldova, 24 November 2016)
Presented by Piroska Östlin, Director and Åsa Nihlén, Technical Officer, Division of Policy and Governance for Health and Well-being, WHO/Europe, at the 66th session of the WHO Regional Committee for Europe.
Presentation by Dr Zsuzsanna Jakab,WHO Regional Director for Europe, at the Third High-level Meeting of the Small Countries Initiative, in Monaco, on 11–12 October 2016
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Annette Verster, WHO
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Presentation - Advancing health literacy and social mobilization for the United Nations 2030 Sustainable Development Goals
18 May 2017, Geneva, Switzerland
By Dr Zsuzsanna Jakab, WHO Regional Director for Europe
Progress in and priorities for implementing the regional plans for the health sector response to HIV and hepatitis, Dr Masoud Dara, Acting Director, Communicable Diseases Department (69th session of the WHO Regional Committee for Europe)
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe, at the 7th Meeting of the European Advisory Committee on Health Research (Copenhagen, Denmark, 6 April 2016)
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe (Positioning the Veneto Region at the core of global and European health policies, 3-4 December 2015, Scuola San Giovanni Evangelista, Venice, Italy)
Health literacy in the WHO European Region, Dr Bente Mikkelsen, Director, Noncommunicable Diseases and Promoting Health through the Life-course / Kristina Mauer-Stender, Acting Director, Information, Evidence, Research and innovation (WHO Regional Office for Europe)
Management of diabetes in malaysia, istanbul 2013[final]Feisul Mustapha
Management of Diabetes in Malaysia. Plenary paper presented by Dato' Sri Dr Hilmi Yahaya, Deputy Minister of Health Malaysia at the International Diabetes Leadership Forum. 15 November 2013. Istanbul, Turkey. Paper was prepared by Dr Zainal Ariffin Omar and myself
Dr Oleg Chestnov, помощник генерального директора
Dr Jill Farrington, и.о. руководителя офиса проекта по НИЗ в Москве
Dr Gauden Galea, директор
Отдел неинфекционных заболеваний и укрепления здоровья на всех этапах жизни
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe, at the 65th session of the WHO Regional Committee for Europe (Vilnius, Lithuania, 14–17 September 2015)
Presentation - Advancing health literacy and social mobilization for the United Nations 2030 Sustainable Development Goals
18 May 2017, Geneva, Switzerland
By Dr Zsuzsanna Jakab, WHO Regional Director for Europe
Progress in and priorities for implementing the regional plans for the health sector response to HIV and hepatitis, Dr Masoud Dara, Acting Director, Communicable Diseases Department (69th session of the WHO Regional Committee for Europe)
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe, at the 7th Meeting of the European Advisory Committee on Health Research (Copenhagen, Denmark, 6 April 2016)
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe (Positioning the Veneto Region at the core of global and European health policies, 3-4 December 2015, Scuola San Giovanni Evangelista, Venice, Italy)
Health literacy in the WHO European Region, Dr Bente Mikkelsen, Director, Noncommunicable Diseases and Promoting Health through the Life-course / Kristina Mauer-Stender, Acting Director, Information, Evidence, Research and innovation (WHO Regional Office for Europe)
Management of diabetes in malaysia, istanbul 2013[final]Feisul Mustapha
Management of Diabetes in Malaysia. Plenary paper presented by Dato' Sri Dr Hilmi Yahaya, Deputy Minister of Health Malaysia at the International Diabetes Leadership Forum. 15 November 2013. Istanbul, Turkey. Paper was prepared by Dr Zainal Ariffin Omar and myself
Dr Oleg Chestnov, помощник генерального директора
Dr Jill Farrington, и.о. руководителя офиса проекта по НИЗ в Москве
Dr Gauden Galea, директор
Отдел неинфекционных заболеваний и укрепления здоровья на всех этапах жизни
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe, at the 65th session of the WHO Regional Committee for Europe (Vilnius, Lithuania, 14–17 September 2015)
Dr Gauden Galea, Director, Noncommunicable Diseases and Promoting Health through the Life-course, WHO Regional Office for Europe - Dr Jo Inchley, HBSC International Coordinator, University of St Andrews
Presentation delivered by Tim Nguyen, Unit leader - Tanja Kuchenmüller, Technical Officer at the 65th session of the WHO Regional Committee for Europe (Vilnius, Lithuania, 14–17 September 2015)
Д-р Florence FUCHS, Штаб-квартира ВОЗ - Шестьдесят пятая сессия Европейского регионального комитета ВОЗ (Вильнюс, Литва, 14–17 сентября 2015 г.) / Presentation delivered by Dr Florence Fuchs, WHO Headquarters, at the 65th session of the WHO Regional Committee for Europe (Vilnius, Lithuania, 14–17 September 2015)
Presentation delivered by Claudia Stein, Director - Division of Information, Evidence, Research and Innovation at the 65th session of the WHO Regional Committee for Europe (Vilnius, Lithuania, 14–17 September 2015)
Presentations delivered by Dr Nedret Emiroglu (Director, Division of Communicable Diseases and Health Security at the WHO Regional Office for Europe) - High-level meeting on refugee and migrant health (23-24 November 2015, Rome, Italy)
Dr Caroline Brown, Programme Manager, Influenza and Other Respiratory Pathogens, Thomas Hofmann, IHR Area Coordinator, Communicable Diseases and Health Security
Presentation delivered by Zsuzsanna Jakab, WHO Regional Director for Europe, at the Meeting of the European Environment and Health Ministerial Board (24 February 2015, Madrid, Spain)
Presentation made by Zsuzsanna Jakab, WHO Regional Director for Europe, at the meeting on Interdepartmental Plan for Public Health of Catalonia (PINSAP) Strategy and Programme, held in Barcelona, Spain on 14 February 2014.
Non-Communicable Diseases: Malaysia in Global Public HealthFeisul Mustapha
Paper presented at a CME Session, held in conjunction with the NIH Research Week 2014, 26 November 2014 at the Institute for Health Management, Bangsar
Presentation delivered by Dr Zsuzsanna Jakab, Regional Director WHO Europe, at the international health forum (Ashgabat, Turkmenistan, 21-22 July 2015)
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe, at the Advanced Training and Conference on Health Economics (24 June 2015, Budapest, Hungary)
Australia's health system needs to better connect the dots in a number of areas. Our work looks at connections between Australian chronic disease targets and indicators, WHO targets and indicators, and national progress.
Reported measles cases for the period November 2020—October 2021 (data as of 02 December 2021).A monthly summary of the epidemiological data on selected vaccine-preventable diseases in the WHO European Region
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
The European health report 2015. Targets and beyond – reaching new frontiers in evidence
1. The European health report 2015
Targets and beyond – reaching new
frontiers in evidence
Claudia Stein
Director
Division of Information, Evidence, Research and Innovation
2. European health reports
What are the European health
reports?
Flagship corporate products of
WHO Europe;
Published once every 3 years;
Major platform for reporting on
Health 2020 progress.
Baseline measurement for
Health 2020: year 2010
3. European health report 2015
Main aims:
• To report on progress towards the Health
2020 targets (since 2010 baseline);
• To reach new frontiers in health
information and ‘evidence for the 21st
century’, including further work
on well-being.
4. Health 2020 targets
1. Reduce premature mortality
2. Increase life expectancy
3. Reduce inequities
4. Enhance well-being
5. Achieve universal health coverage
6. Establish national targets set by Member States
5. Target 1: Reduce premature mortality
Target: 1.5% relative annual
reduction in premature mortality
from cardiovascular disease, cancer,
diabetes and chronic respiratory
diseases until 2020.
Indicator: age-standardized death
rate per 100,000 in people aged 30-
69 for cardiovascular diseases,
cancer, diabetes mellitus and chronic
respiratory diseases combined.
6. Mortality from external causes
Standardized death rate
per 100 000
Biggest
reductions in:
Russian
Federation,
Latvia,
Estonia,
Ukraine, and
Kazakhstan
8. Changes in tobacco smoking prevalence
since 2010
Biggest
reductions in:
Georgia,
Belarus,
Ukraine,
Russian
Federation
and
Kazakhstan
9. Target 2: Increase life expectancy
Target:
continued
increase in life
expectancy at
current rate (the
annual rate
during 2006-
2010), coupled
with reducing
differences in
life expectancy
in the European
Region.
10. Target 4: Enhance well-being
• Subjective and
objective
well-being
• (How) can we
compare?
• How can we best
communicate
about well-being?
WHO will engage in further work on the cultural contexts
of health and well-being
11. Cultural contexts of well-being
Conclusions from the report:
• Well-being is a vital component of health
• …and it can be measured.
• But cultural differences must be better
understood
• …and more innovative reporting
strategies are need.
12. Cultural contexts of well-being
Expert Group on Cultural Contexts of Health and
Well-being. 1st meeting January 2015: Main
recommendations:
• Explore different types of qualitative evidence more fully
• Commission further work in the area of culture and health
• Adopt the UNESCO definition of culture
• Investigate cultural contexts of health more systematically
• Use a multisectoral and multidisciplinary integrated research
approach.
14. 0% 10% 20% 30% 40% 50% 60% 70%
No
Yes, included elsewhere
Yes, stand alone
Policy addressing health inequity or social determinants of health exists
All answers (n=31 and 36 for 2010 and 2013, respectively)
2013
2010
0% 10% 20% 30% 40% 50% 60%
No, and not planned for the future
No, but planned for the future
Indicators defined
Targets defined
National or subnational target setting process exists
All answers (n=31 and 36 for 2010 and 2013, respectively)
2013
2010
0% 10% 20% 30% 40% 50% 60% 70%
No and not planned for the future
No, but planned for the future
Yes, another strategy
Yes, comprehensive health policy
National health policy is aligned with H2020
All answers (n=31 and 36 for 2010 and 2013, respectively)
2013
2010
0% 10% 20% 30% 40% 50% 60%
No, and not planned for the future
Yes, in process
Yes, adopted
There is ahealthpolicy accountability mechanisminplace
All answers (n=31 and 36 for 2010 and 2013, respectively)
2013
2010
Source: WHO. Qualitative indicators for Health 2020 policy targets monitoring, 2014
Online survey
Target 6: Alignment with Health 2020
15. Moving forward: working together
• Broad international cooperation is
required to tackle current health
information challenges efficiently and
sustainably;
• WHO Europe, European Commission and
OECD are working together towards a
single, integrated health information
system for the WHO European Region.
16. Conclusions
• The European Region is on track to achieve the Health 2020 targets
but much needs to be done to reduce inequities;
• To inform the implementation of Health 2020 adequately, data
collections need to be strengthened and new health monitoring
approaches explored;
• Enhanced international collaboration is required to move the health
information research and development agenda forward in the
Region.
17. Please use our products!
All products available at:
http://www.euro.who.int/
en/data-and-
evidence/european-
health-report2015
Factsheets
No data for Andorra, Bosnia and Herzegovina, Monaco, Turkmenistan
For a few countries a more recent year than 2000 was used as baseline (as there were no data for 2000 for those countries; Belgium Cyprus and Turkey).
Overweight and obesity is BMI ≥ 25
Prevalence overweight and obesity in Americas: 61,3%
Men in European Region: 62,6%
Women in European Region: 54.9%
Rates of alcohol consumption and tobacco use are highest globally.
Overweight and obesity; slightly behind the Americas.
Data availability too limited to draw conclusions about whether we are on-track to reach the target (no Regional average for 2012 yet).
Well-being is a vital component of health
It’s part of WHO’s original, visionary definition of health. Without this focus, WHO is a World Death, Disease, and Disability Organisation.
Higher levels of well-being are consistently associated with decreased risks of disease, illness and injury, better immune functioning, speedier recovery and increased longevity.
It’s a unifying concept (linked to the environment, education, culture, finance) that provides important opportunities for using a whole-of-government approach.
…and it can be measured
Over 40 years of social indicator work has demonstrated that well-being can be measured reliably in local and even national contexts.
But cultural differences must be better understood
Cultural contexts strongly influence well-being, making cross-country comparisons difficult. For WHO to be able to use well-being more effectively as a policy tool, these contexts need to be better understood.
This is particularly true in the European Regional context, where little work has been done which compares the different ways in which well-being is constructed in different countries.
…and more innovative reporting strategies are need.
Well-being resists top down approaches, which miss out on the rich diversity of cultural contexts within which health and well-being are situated. Engaging meaningfully with well-being means that we have to use more participatory and inclusive approach to reporting on well-being.
Adopt the UNESCO definition of culture
From the UNESCO Universal Declaration on Cultural Diversity, 2001
Culture is “the set of distinctive spiritual, material, intellectual and emotional features of society or a social group, and that it encompasses, in addition to art and literature, lifestyles, ways of living together, value systems, traditions and beliefs”.
Investigate cultural contexts in health more systematically
An increasing number of voices in the public health community have been calling for the need to consider the important role less tangible health determinants, such as culture, play in the provisioning of equitable healthcare.
In line with conclusions from UCL/Lancet commission on Culture and Health, which evidences the important role cultural contexts play in relation to health, the Expert Group recommended that a more systematic exploration of cultural contexts in health an well-being was necessary.
Employ a multidisciplinary, integrated research approach
This shift towards the subjective, as in the case of subjective well-being, is creating a need for more capacity to tap into relevant research from the humanities and wider social sciences, which are well placed to help explore the meanings people create around experiences of disease, health and well-being.
Explore different types of qualitative evidence more fully
To engage with the full complexity of subjective well-being, a more sustained use of different types of qualitative evidence is necessary. This includes investigating how of historical records, cultural outputs, and anthropological observations might help us to understand what “being well” in the European context actually means.
Use a participatory approach to communicate about well-being
WHO should explore culture-centred, participatory approaches that engage local communities in sensitive and measured ways in order to explore what it means to be well and healthy.
Communication about well-being initiatives should be two-way. Effective communication about well-being will require listening to countries, groups and people about their own definitions and explorations of well-being.
We see a similar pattern for the indicator on number of MS with policies aligned with Health 2020, implementation plans and accountability mechanisms.
Dedicated data collection for qualitative indicators (web based tool) initiated towards Core Health Indicators 2014 with special focus on Health 2020 indicators
Demonstrated evidence of increased inclusion of Health 2020 principles and recommendations in national health policies between 2010 and 2013